Business Wire

MI-EATON

Share
Eaton to Display Terminals and Connectors at CONEXPO-CON/AGG Trade Show

Intelligent power management company Eaton today announced it will be displaying its line of power connectors and terminals for electrified and internal combustion construction and off-highway vehicles at the CONEXPO-CON/AGG construction trade show March 14-18 in Las Vegas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230309005192/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Royal Power Solutions large LP12, LP16 and RD14 terminals are designed for vehicles typically used in construction and off-highway fields. (Photo: Business Wire)

The connectors were designed and developed by Royal Power Solutions (RPS), which Eaton acquired in 2022. Established in 1938, RPS is a global leader in the development and production of critical high-precision power- and signal-distribution terminals and connectors.

“The construction industry, like many others, is transitioning to electrification. Eaton’s global and diverse footprint has broadened our reach and ability to grow in this market,” said Chris Mancuso, general manager, Power Connections, Eaton’s eMobility business. “As the construction industry electrifies, the need for differentiating terminals and connectors evolves in parallel. We have seen a similar transition in the automotive market.”

Eaton’s portfolio of industry-leading electrical solutions includes terminals, connectors and other electrical components designed to handle current levels up to 500 amps. Among those components are stamped battery and eyelet terminals that can withstand vibration and harsh environments, making them ideal for commercial and off-highway vehicles.

High Power Lock Box connectors provide protection, superior performance

Eaton’s high power lock box (HPLB) power connectors are ideal for current and future electrified construction and off-highway vehicle solutions and can help reduce common warranty issues. The HPLB connectors offer a space-saving profile, superior performance, cost savings and reduced manufacturing complexity. The HPLB terminals provide efficiency, reliability and have stronger current carrying capabilities compared to terminals on the market today.

The HPLB terminal system forms a connection in a unique way that provides improved contact force as the temperature increases. Unlike traditional competitors’ box-and-blade or pin-and-socket terminal connections, Eaton’s HPLB terminals use an inverted contact system approach for a stronger connection.

Terminals designed for construction, aggregate industries

Part of the HPLB product line, the low-profile 12 (LP12), low-profile 16 (LP16) and round 14 (RD14) terminals are larger and designed for vehicles typically used in construction and agricultural fields. Able to carry up to 500 amps, the HPLB terminals allow global customers to simplify the manufacturing process and open new areas of opportunity for electrified off-highway vehicles.

Busbars feature low profile, flexibility to meet design requirements

Another technology now available to Eaton’s construction and off-highway vehicle customers is RigiFlex busbars, which can be manufactured in copper or aluminum, depending on customer requirements. With a unique, simple, single piece flow manufacturing process, Eaton can scale volume to meet any customer specification.

The RigiFlex busbar is rigid in some areas, but flexible in sections that require expansion, contraction or elevated changes in the system design. This flexibility also works well across the battery pack in areas that need to comply with expansion and contraction during charging and discharging cycles due to changing cell thicknesses.

Low-profile busbars enable space-efficient design without heat sinks for weight savings. Eaton also can produce busbars with a level of flatness over length unmatched by competitors.

“When off-highway equipment is assembled, it’s largely done manually since robots have difficulty handling round wires, which are hard for them to grasp,” Mancuso said. “When employing high power lock box terminals our Rigiflex busbars improve the assembly process, safety and time to complete the manufacturing process and with less equipment and fewer assembly personnel.”

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.

Founded in 1911, Eaton is marking its 100th anniversary of being listed on the New York Stock Exchange. We reported revenues of $20.8 billion in 2022 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005192/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye